Cantor Fitzgerald Maintains a 'Buy' on Warner Chilcott (WCRX); Let's Make It Official
Tweet Send to a FriendGet Alerts WCRX Hot Sheet
Price: $20.00 --0%
Rating Summary:
5 Buy, 10 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
5 Buy, 10 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Trade WCRX Now!
Cantor Fitzgerald maintains a 'Buy' on Warner Chilcott (NASDAQ: WCRX) price target raised from $22 to $26.
Analyst, Irina Rivkind, said, "The announcement indicating that management has retained an investment bank to evaluate its options clearly comes after the company spent over a year searching for acquisition targets. Management has previously publicly stated that it has also contemplated the divestiture of its Actonel franchise. We therefore think that management has been reviewing its options for some time and has a sober view of its risks and opportunities. With this "process" announcement, management is knowingly disrupting operations in the field and in its headquarters. We therefore believe that the company is fairly progressed in its thinking. If management wanted to issue a special dividend to its shareholders, we think that the company could have quietly done so on its own (like in 2010), which would have been far less disruptive to the business."
Rivkind sees Bayer (OTC: BAYRY), Teva (Nasdaq: TEVA), Watson (NYSE: WPI), J&J (NYSE: JNJ) or Endo (Nasdaq: ENDP) as potential buyers of WCRX's Women's Health business.
Asacol may be considered by AstraZeneca (NYSE: AZN) Takeda, or Forest Labs (NYSE: FRX).
Cantor lowers FY12 EPS estimate from $3.66 to $3.60 and FY13 from $3.27 to $3.11.
For an analyst ratings summary and ratings history on Warner Chilcott click here. For more ratings news on Warner Chilcott click here.
Shares of Warner Chilcott closed at $21.81 yesterday, with a 52 week range of $12.90-$25.92.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Irina Rivkind, said, "The announcement indicating that management has retained an investment bank to evaluate its options clearly comes after the company spent over a year searching for acquisition targets. Management has previously publicly stated that it has also contemplated the divestiture of its Actonel franchise. We therefore think that management has been reviewing its options for some time and has a sober view of its risks and opportunities. With this "process" announcement, management is knowingly disrupting operations in the field and in its headquarters. We therefore believe that the company is fairly progressed in its thinking. If management wanted to issue a special dividend to its shareholders, we think that the company could have quietly done so on its own (like in 2010), which would have been far less disruptive to the business."
Rivkind sees Bayer (OTC: BAYRY), Teva (Nasdaq: TEVA), Watson (NYSE: WPI), J&J (NYSE: JNJ) or Endo (Nasdaq: ENDP) as potential buyers of WCRX's Women's Health business.
Asacol may be considered by AstraZeneca (NYSE: AZN) Takeda, or Forest Labs (NYSE: FRX).
Cantor lowers FY12 EPS estimate from $3.66 to $3.60 and FY13 from $3.27 to $3.11.
For an analyst ratings summary and ratings history on Warner Chilcott click here. For more ratings news on Warner Chilcott click here.
Shares of Warner Chilcott closed at $21.81 yesterday, with a 52 week range of $12.90-$25.92.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
- UPDATE: Crash in American Electric Power (AEP) & NextEra Energy (NEE) Adds to Jitters
- Under Armour (UA) Estimates, Price Targer Raised at Sterne Agee
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Trader TalkRelated Entities
Cantor Fitzgerald, Dividend
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
